s
CJ Bioscience to Present Preclinical Data on Inflammatory Bowel Disease Pipeline Candidate CJRB-201 at ‘ECCO 2025’; Clinical Entry Targeted for 2026
18-02-2025, 12:54
SEOUL, South Korea, Feb. 18, 2025 /PRNewswire/ — CJ Bioscience announced today that it will present preclinical data on its novel drug candidate CJRB-201 at the European Crohn’s and Colitis Organization (ECCO) 2025, set to take place from February 19 to 22 in Berlin, Germany. ECCO is a leading international conference in the field of […] L'articolo CJ Bioscience to Present Preclinical Data on Inflammatory Bowel Disease Pipeline Candidate CJRB-201 at ‘ECCO 2025’; Clinical Entry Targeted for 2026 proviene da La Ragione.
CONTINUA A LEGGERE
13
0
0
Guarda anche
Wall Street Italia
Arterra Bioscience, fatturato in crescita del 28,21% nel 2024
Il Resto del Carlino
